References
- Coopman V, Cordonnier J. “Spice-like” herbal incense laced with the synthetic opioid U-47700. Toxicologie Analytique et Clinique 2018;30(1):75–9. doi: 10.1016/j.toxac.2017.07.004.
- European Monitoring Centre for Drugs and Drug Addiction. (2018) European drug report 2018: trends and developments. Luxembourg: Publications Office of the European Union. http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf
- Zobnin YV, Stadler EM. Acute poisoning with synthetic cannabinoids (“spice”). Sibirskiy meditsinskiy zhurnal (Irkutsk) 2014;8:130–5.
- Wolitzky-Taylor K, McBeth J, Guillot CR, Stone MD, Kirkpatrick MG, Zvolensky MJ, Buckner JD, Leventhal AM. Transdiagnostic processes linking anxiety symptoms and substance use problems among adolescents. J Addict Dis. 2016;18:1–12. [Epub ahead of print].
- Sherif M, Radhakrishnan R, D’Souza DC, Ranganathan M. Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry 2016;79:526–38. doi: 10.1016/j.biopsych.2016.01.011.
- Manseau MW, Rajparia A, Joseph A, Azarchi S, Goff D, Satodiya R, Lewis CF. Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. Subst Use Misuse 2017;52:822–5. doi: 10.1080/10826084.2016.1263663.
- De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D’Souza DC. The psychiatric consequences of cannabinoids. Clin Ther. 2018;40(9):1448–56. doi: 10.1016/j.clinthera.2018.03.013.
- Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018;50(1):65–73. doi: 10.1080/03602532.2018.1428343.
- Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011;6(7):e21917. doi: 10.1371/journal.pone.0021917.
- Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. Zombie; outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017;376:235–42. doi: 10.1056/NEJMoa1610300.
- Conrad K. Die beginnende Schizophrenic. Stuttgart: Georg Thieme, 1958. 315s.